Percutaneous endoscopic gastrostomy |
Prevention of peristomal infection |
Cefazolin 1-g i.v. single dose 30 min before procedure, cefuroxime 1.5-g i.v. single dose, or amoxicillin-clavulanate 1.2-g i.v. single dose |
Esophageal sclerotherapy, variceal ligation |
Prevention of procedure-related bacteremia and peritonitis |
Piperacillin-tazobactam 4.5-g i.v. single dose (some give 3 times daily), cefotaxime 2-g i.v. single dose, or ceftriaxone 2-g i.v. single dose |
Cirrhosis with acute variceal bleeding |
Esophageal dilatation |
|
|
Benign/malignant stricture of the esophagus |
|
|
Endoscopic retrograde cholangiopancreaticography |
|
|
Biliary obstruction (e.g., primary sclerosing cholangitis and/or hilar cholangiocarcinoma) when complete biliary drainage is unlikely to be achieved |
Prevention of cholangitis |
Ciprofloxacin 750-mg single dose orally 1.5–2 h before procedure, piperacillin-tazobactam 4.5-g i.v. single dose 1 h before procedure, or i.v. single dose of gentamicin at 1.5 mg/kg of body weight at time of sedation |
Communicating pancreatic cysts/pseudocysts |
Prevention of cyst infection |
See above (“Biliary obstruction”) |
Biliary complications after liver transplantation |
Prevention of cholangitis |
Ciprofloxacin 750-mg single dose orally 1.5–2 h before procedure, gentamicin 1.5-mg/kg i.v. single dose at the time of sedation plus amoxicillin 1-g i.v. single dose, or vancomycin at 20 mg/kg i.v. over at least 1 h |
Any gastrointestinal endoscopic procedure |
|
|
Patients with cardiovascular risk factors |
Prevention of infective endocarditis |
Not recommended |
Patients with synthetic vascular graft and other cardiovascular devices |
Prevention of graft and device infection |
Not recommended |
Patients with prosthetic joints |
Prevention of septic arthritis |
Not recommended |